DK3551629T3 - Oxabicycloheptaner til modulering af immunrespons - Google Patents
Oxabicycloheptaner til modulering af immunrespons Download PDFInfo
- Publication number
- DK3551629T3 DK3551629T3 DK17879038.2T DK17879038T DK3551629T3 DK 3551629 T3 DK3551629 T3 DK 3551629T3 DK 17879038 T DK17879038 T DK 17879038T DK 3551629 T3 DK3551629 T3 DK 3551629T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxabicycloheptanes
- modulation
- immune response
- immune
- response
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662497949P | 2016-12-08 | 2016-12-08 | |
US201762465001P | 2017-02-28 | 2017-02-28 | |
US201762545373P | 2017-08-14 | 2017-08-14 | |
PCT/US2017/065270 WO2018107004A1 (en) | 2016-12-08 | 2017-12-08 | Oxabicycloheptanes for modulation of immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3551629T3 true DK3551629T3 (da) | 2024-02-12 |
Family
ID=62491355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17879038.2T DK3551629T3 (da) | 2016-12-08 | 2017-12-08 | Oxabicycloheptaner til modulering af immunrespons |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200069680A1 (da) |
EP (2) | EP4324477A3 (da) |
JP (2) | JP7246309B2 (da) |
KR (2) | KR20240042151A (da) |
CN (2) | CN116585480A (da) |
AU (1) | AU2017370731B2 (da) |
BR (1) | BR112019011627A2 (da) |
CA (1) | CA3046515A1 (da) |
DK (1) | DK3551629T3 (da) |
ES (1) | ES2970913T3 (da) |
IL (2) | IL290857B2 (da) |
MX (1) | MX2019006694A (da) |
WO (1) | WO2018107004A1 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2984267T3 (es) | 2013-04-09 | 2024-10-29 | Lixte Biotechnology Inc | Formulaciones de oxabicicloheptanos y oxabicicloheptenos |
MX2021012440A (es) | 2015-05-15 | 2022-06-28 | Lixte Biotechnology Inc | Farmacos precursores de oxabicicloheptanos. |
KR102723511B1 (ko) | 2019-08-13 | 2024-10-28 | 주식회사 엘지에너지솔루션 | 전극 스크랩 재활용 방법 및 이를 이용한 전극 제조 방법 |
WO2024097784A2 (en) * | 2022-11-03 | 2024-05-10 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for treating refractory cancers |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166531A1 (en) * | 2001-02-16 | 2003-09-04 | Genetics Institute, Inc. | Methods for modulating an immune response by modulating the interaction between CTLA4 and PP2A |
EP2124550B1 (en) * | 2007-02-06 | 2017-04-19 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US8227473B2 (en) * | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
GB0903325D0 (en) | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
EP2867239A4 (en) * | 2012-06-29 | 2015-12-23 | Lixte Biotechnology Inc | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES |
EP2870161B1 (en) * | 2012-06-29 | 2018-08-08 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury |
ES2984267T3 (es) * | 2013-04-09 | 2024-10-29 | Lixte Biotechnology Inc | Formulaciones de oxabicicloheptanos y oxabicicloheptenos |
US20160264593A1 (en) | 2013-11-15 | 2016-09-15 | John S. Kovach | Protein phosphatase inhibitors that cross the blood brain barrier |
EP3157336A4 (en) * | 2014-06-20 | 2018-01-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer |
WO2016040877A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
KR20170138477A (ko) * | 2015-04-17 | 2017-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
MX2021012440A (es) | 2015-05-15 | 2022-06-28 | Lixte Biotechnology Inc | Farmacos precursores de oxabicicloheptanos. |
-
2017
- 2017-12-08 DK DK17879038.2T patent/DK3551629T3/da active
- 2017-12-08 CA CA3046515A patent/CA3046515A1/en active Pending
- 2017-12-08 WO PCT/US2017/065270 patent/WO2018107004A1/en unknown
- 2017-12-08 IL IL290857A patent/IL290857B2/en unknown
- 2017-12-08 BR BR112019011627-3A patent/BR112019011627A2/pt unknown
- 2017-12-08 CN CN202310498623.5A patent/CN116585480A/zh active Pending
- 2017-12-08 CN CN201780084881.1A patent/CN110234647B/zh active Active
- 2017-12-08 AU AU2017370731A patent/AU2017370731B2/en active Active
- 2017-12-08 KR KR1020247008982A patent/KR20240042151A/ko active Search and Examination
- 2017-12-08 US US16/467,721 patent/US20200069680A1/en active Pending
- 2017-12-08 ES ES17879038T patent/ES2970913T3/es active Active
- 2017-12-08 MX MX2019006694A patent/MX2019006694A/es unknown
- 2017-12-08 EP EP23202240.0A patent/EP4324477A3/en active Pending
- 2017-12-08 KR KR1020197019763A patent/KR20190098995A/ko active Application Filing
- 2017-12-08 JP JP2019530702A patent/JP7246309B2/ja active Active
- 2017-12-08 EP EP17879038.2A patent/EP3551629B1/en active Active
-
2019
- 2019-06-06 IL IL267134A patent/IL267134B/en unknown
-
2023
- 2023-01-12 JP JP2023003205A patent/JP2023036999A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200069680A1 (en) | 2020-03-05 |
IL290857B (en) | 2022-11-01 |
AU2017370731A1 (en) | 2019-07-04 |
EP3551629A4 (en) | 2020-07-29 |
CA3046515A1 (en) | 2018-06-14 |
CN110234647B (zh) | 2023-05-23 |
BR112019011627A2 (pt) | 2019-11-12 |
CN116585480A (zh) | 2023-08-15 |
IL290857A (en) | 2022-04-01 |
KR20240042151A (ko) | 2024-04-01 |
AU2017370731B2 (en) | 2022-06-02 |
CN110234647A (zh) | 2019-09-13 |
EP4324477A2 (en) | 2024-02-21 |
EP4324477A3 (en) | 2024-05-22 |
IL267134B (en) | 2022-04-01 |
JP2023036999A (ja) | 2023-03-14 |
KR20190098995A (ko) | 2019-08-23 |
JP7246309B2 (ja) | 2023-03-27 |
MX2019006694A (es) | 2019-08-21 |
EP3551629B1 (en) | 2023-11-15 |
WO2018107004A1 (en) | 2018-06-14 |
EP3551629A1 (en) | 2019-10-16 |
IL267134A (en) | 2019-08-29 |
JP2020502094A (ja) | 2020-01-23 |
IL290857B2 (en) | 2023-03-01 |
ES2970913T3 (es) | 2024-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
DK3463248T3 (da) | Anordnnger til anvendelse af lægemiddelanordninger | |
DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
DK3262071T3 (da) | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater | |
DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
DK3126373T3 (da) | Fremgangsmåde til fremstilling af amg 416 | |
DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
DK3507408T3 (da) | Fremgangsmåde til fremstilling af nonwoven | |
DK3452507T3 (da) | Tau-immunoterapi | |
DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
DK3668358T3 (da) | Indretning til tilberedning af varme drikke | |
DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
DK3166611T3 (da) | Fremgangsmåde til fremstilling af 4-alkoxy-3-hydroxypicolinsyrer | |
DK3479159T3 (da) | Moduleret fabry-pérot | |
DK3177931T3 (da) | Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder | |
DK3544416T3 (da) | Applikation af væsker | |
DK3463001T3 (da) | Kogegrej | |
IL290857A (en) | Oxabicycloheptanes for immune response modulation |